Hua Bian

Dr. Hua Bian


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
QLQin Lv
Qin Lv
HBHua Bian
Hua Bian
LYLei Yang
Lei Yang
KGKe‐Lei Guo
Ke‐Lei Guo
LTLing‐Ling Tao
Ling‐Ling Tao
Esophageal cancer is one of the most common tumor in the world, and the morbidity rate is as high as 100/100 000 in some parts of China. Therefore, it is important and urgent to explore the pathogenesis of esophageal cancer and find new therapeutic targets for esophageal cancer. In this study, we found that a novel tumor suppressor SPINK5 is significantly reduced in the development of esophageal cancer, and is closely related to the pathological differentiation and lymph node metastasis of esophageal cancer via bioinformatics analysis and esophageal cancer tissue array. Further studies have found that SPINK5 is closely related to Wnt/β‐catenin signaling pathway by bioinformatics analysis and western blot. In esophageal cancer cells, SPINK5 overexpression can inhibit Wnt/β‐catenin signaling pathway. Combined with LiCl or MG‐132 treatment, SPINK5 can inhibit GSK3β phosphorylation and promote β‐catenin protein degradation, thus inhibit Wnt/β‐catenin signaling pathway. In vivo study, SPINK5 overexpression can significantly inhibit the growth of esophageal cancer cells. Our study shows that SPINK5 can inhibit the proliferation, migration, and invasion of esophageal cancer cells by inhibiting Wnt/β‐catenin signaling pathway, and thus plays an important role in the development of esophageal cancer, and may serve as a treatment target of esophageal cancer.

23 September 2025 in Food Chemistry: X
Verified
Journal Article
Open access
LZLei Zhao
Lei Zhao
YZYa Zhou
Ya Zhou
WYWeiguo Yue
Weiguo Yue
QSQingshan Shen
Qingshan Shen
JKJingxuan Ke
Jingxuan Ke
HBHua Bian
Hua Bian
Natural phenolics are emerging as promising clean-label antimicrobials, yet evidence for their multitarget mechanisms remains scattered. This review synthesizes 158 studies (2013–2025) on Escherichia coli, Staphylococcus aureus, and related pathogens. Three converging antibacterial targets are identified: ROS generation (72 % of phenolics), membrane disruption (58 %), and DNA interaction (41 %). Compounds such as bisdemethoxycurcumin, gallic acid, thymol, and Epigallocatechin gallate (EGCG) act across all targets, reducing bacterial counts by up to 4 log CFU/mL at ≤2 × MIC. A cascade mechanism is proposed: ROS triggers lipid peroxidation, weakening membranes, enhancing phenolic uptake, and accelerating DNA damage. Food matrix factors (pH, fat, water activity, microbiota) can suppress efficacy by up to 90 %. Emerging delivery strategies—nanoemulsions, biopolymer capsules, and active films—partially restore function. This review integrates molecular insights with food system data, offering a practical framework for designing robust phenolic-based antimicrobials.

8 June 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
WZWenhua Zang
Wenhua Zang
HBHua Bian
Hua Bian
XHXianzhang Huang
Xianzhang Huang
GYGang Yin
Gang Yin
CZChaoyun Zhang
Chaoyun Zhang
DTDecai Tang
Decai Tang
Background/Aim: The aim of the present study was to investigate the vascular normalization effect of traditional Chinese medicine Astragalus membranaceus (AM) and Curcuma wenyujin (CW) on tumor-derived endothelial cells (TECs). Materials and Methods: TECs were isolated from the xenografted HCC cell line HepG2 expressing red fluorescent protein (RFP). The effect of AM and CW on TECs proliferation was measured using the CCK8 assay. The vascular normalization potential of AM and CW was assessed using a tube formation assay. Immunocytochemistry was performed to assess the effect of AM and CW on the expression of angiogenic maker CD34 and hypoxia-inducible factor HIF1a. Results: The isolated TECs and endothelioma (EOMA) cells did not differ with regard to the expression levels of endothelial markers CD34, VEGFR-1, VEGFR-2, PDGFR-α and PDGFR-β. All AM, CW, AM+CW and Nintedanib (Nin) showed a dose-dependent increasing inhibition effect on either TECs or EOMA cells. AM, CW and AM+CW significantly reduced HIF1a expression, increased CD34 expression and enhanced endothelial network formation in TECs or EOMA cells compared to the control. Conclusion: AM and CW promoted vascular normalization in tumor-derived endothelial cells of HCC, through increased expression of CD34 and reduced expression of HIF1a.

29 January 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
RDRuijuan Du
Ruijuan Du
KLKai Li
Kai Li
KGKeLei Guo
KeLei Guo
ZCZhiguo Chen
Zhiguo Chen
XZXulin Zhao
Xulin Zhao
HBHua Bian
Hua Bian
Transducin beta-like 1X-related protein 1 (TBL1XR1) was discovered two decades ago and was implicated as part of the nuclear transcription corepressor complex. Over the past 20 years, the emerging oncogenic function of TBL1XR1 in cancer development has been discovered. Recent studies have highlighted that the genetic aberrations of TBL1XR1 in cancers, especially in hematologic tumors, are closely associated with tumorigenesis. In solid tumors, TBL1XR1 is proposed to be a promising prognostic biomarker due to the correlation between abnormal expression and clinicopathological parameters. Post-transcriptional and post-translational modification are responsible for the expression and function of TBL1XR1 in cancer. TBL1XR1 exerts its functional role in various processes that involves cell cycle and apoptosis, cell proliferation, resistance to chemotherapy and radiotherapy, cell migration and invasion, stemness and angiogenesis. Multitude of cancer-related signaling cascades like Wnt-β-catenin, PI3K/AKT, ERK, VEGF, NF-κB, STAT3 and gonadal hormone signaling pathways are tightly modulated by TBL1XR1. This review provided a comprehensive overview of TBL1XR1 in tumorigenesis, shedding new light on TBL1XR1 as a promising diagnostic biomarker and druggable target in cancer.

17 February 2020 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
LHLi Han
Li Han
XCXueyun Cao
Xueyun Cao
ZCZhong Chen
Zhong Chen
XGXiaojuan Guo
Xiaojuan Guo
LYLei Yang
Lei Yang
HBHua Bian
Hua Bian
Background: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats exposed to Guizhi Fuling Wan extract (GFWE) in cisplatin-resistant human ovarian cancer SKOV3/DDP cells; the proteins examined included phosphatase and tensin homolog (PTEN) and metadherin (MTDH), and the possible protein interaction between PTEN and MTDH was explored. Methods: GFWE was administered to healthy Wistar rats, and the sera were collected after five days. The PubMed and CNKI databases were searched for literature on the bioactive blood components in the sera. The systemsDock website was used to predict potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses were used to analyze the mRNA and protein levels of MTDH and PTEN. Laser confocal microscopy and coimmunoprecipitation (co-IP) were used to analyze the colocalization and interaction between MTDH and PTEN. Results: Sixteen bioactive compounds were identified in GFWE sera after searching the PubMed and CNKI databases. The systemsDock website predicted the potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses showed decreased MTDH expression and increased PTEN expression in the sera. Laser confocal microscopy images and coimmunoprecipitation (co-IP) analyses demonstrated that a colocalization and interaction occurred between MTDH and PTEN, and the addition of the sera changed the interaction status. Conclusions: GFWE restored sensitivity to cisplatin by inhibiting MTDH expression, inducing PTEN expression, and improving the interaction between MTDH and PTEN in SKOV3/DDP cells, and these proteins and their interaction may serve as potential targets for cancer treatment. The sera may represent a new source of anticancer compounds that could help to manage chemoresistance more efficiently and safely.

23 June 2022 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
LHLi Han
Li Han
XGXiaojuan Guo
Xiaojuan Guo
RDRuijuan Du
Ruijuan Du
KGKelei Guo
Kelei Guo
PQPei Qi
Pei Qi
HBHua Bian
Hua Bian
Background: Studies have revealed the implications of cancer-associated fibroblasts (CAFs) in tumor progression, metastasis, and treatment resistance. Here, in silico analyses were performed to reveal the key genes and pathways by which CAFs affected chemoresistance in ovarian cancer. Methods: Candidate genes were obtained from the intersected differentially expressed genes in ovarian cancer, ovarian cancer chemoresistance, and ovarian CAF-related microarrays and chemoresistance-related genes from GeneCards databases. Kyoto Encyclopedia of Genes and Genomes enrichment analysis and Gene Set Enrichment Analysis were employed to identify the pathways engaged in ovarian cancer chemoresistance and ovarian CAF-related pathways. The top genes with high Degree in the protein-protein interaction network were intersected with the top genes enriched in the key pathways, followed by correlation analyses between key genes and chemotherapeutic response. The expression profiles of key genes were obtained from Human Protein Atlas database and TCGA-ovarian cancer data. Results: p53, cell cycle, PI3K-Akt, and MAPK pathways were the key pathways related to the implication of CAFs in ovarian cancer chemoresistance. 276 candidate genes differentially expressed in CAFs were associated with ovarian cancer chemoresistance. MYC, IGF1, HRAS, CCND1, AKT1, RAC1, KDR, FGF2, FAS, and EGFR were enriched in the key chemoresistance-related ways. Furthermore, MYC, EGFR, CCND1 exhibited close association with chemotherapeutic response to platinum and showed a high expression in ovarian cancer tissues and platinum-resistant ovarian cancer cells. Conclusion: The study suggests the key genes (MYC, EGFR, and CCND1) and pathways (p53, cell cycle, PI3K-Akt, and MAPK) responsible for the effect of CAFs on ovarian cancer chemoresistance.